Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00825370 · ClinicalTrials.gov registry record · Phase 3

Protocolized vs Discretionary Use of Opioids in Acute Pain

A Phase 3 study of Pain, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 3
Development phase
350
Enrollment target
1
Study location

NCT00825370 is a Phase 3 study of Pain that has completed, run by Montefiore Medical Center. The registered enrollment target is 350 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (16% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00825370, a Phase 3 study of Pain, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
350 participants
Enrollment target
1
Study location

Study Summary

We are testing whether patients who received protocolized pain management (1 mg of IV hydromorphone followed by an additional 1 mg Intravenous (IV) hydromorphone 15 minutes later if the patients wants more) will have better pain relief and no more adverse events than patients receiving discretionary care, in which the patients receives whatever IV opioid the treating physician wants to give, in whatever dose.

Conditions Studied

Interventions

  • DRUG Hydromorphone
  • DRUG IV opioid

Study Locations (1)

New York

  • Montefiore Medical Center Emergency Department - The Bronx

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2008-10
Est. Completion 2009-05
Phase Phase 3

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00825370

The ClinicalTrials.gov registry entry for NCT00825370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 303-participant average among 374 other Pain trials with a reported enrollment target (16% higher). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Hydromorphone is the first listed.

NCT00825370 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00825370 about?

NCT00825370 is a clinical study titled "Protocolized vs Discretionary Use of Opioids in Acute Pain". We are testing whether patients who received protocolized pain management (1 mg of IV hydromorphone followed by an additional 1 mg Intravenous (IV) hydromorphone 15 minutes later if the patients wants more) will have better pain relief and no more adverse events than patients receiving discretionary...

What is the current status of trial NCT00825370?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2008-10. Estimated completion is 2009-05.

What conditions does trial NCT00825370 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00825370?

The interventions under investigation include: Hydromorphone (DRUG), IV opioid (DRUG).

Who is sponsoring clinical trial NCT00825370?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00825370 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.